These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25732554)

  • 41. Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain.
    Qi J; Gou Y; Zhang Y; Yang K; Chen S; Liu L; Wu X; Wang T; Zhang W; Yang F
    J Med Chem; 2016 Aug; 59(16):7497-511. PubMed ID: 27441502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain.
    Qi J; Zhang Y; Gou Y; Zhang Z; Zhou Z; Wu X; Yang F; Liang H
    Mol Pharm; 2016 May; 13(5):1501-7. PubMed ID: 27017838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Designing biotin-human serum albumin nanoparticles to enhance the targeting ability of binuclear ruthenium(III) compound.
    Jiang M; Li S; Wu J; Li W; Wen XA; Liang H; Yang F
    J Inorg Biochem; 2021 Feb; 215():111318. PubMed ID: 33301985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential anti-tumour agents: cytotoxic activity and human serum albumin binding mechanism.
    Demoro B; de Almeida RF; Marques F; Matos CP; Otero L; Costa Pessoa J; Santos I; Rodríguez A; Moreno V; Lorenzo J; Gambino D; Tomaz AI
    Dalton Trans; 2013 May; 42(19):7131-46. PubMed ID: 23519281
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Titanocene anticancer complexes and their binding mode of action to human serum albumin: a computational study.
    Sarsam SW; Nutt DR; Strohfeldt K; Watson KA
    Metallomics; 2011 Feb; 3(2):152-61. PubMed ID: 21210044
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multispectroscopic Investigation of the Interaction Between two Ruthenium(II) Arene Complexes of Curcumin Analogs and Human Serum Albumin.
    Huang S; Peng S; Zhu F; Lei X; Xiao Q; Su W; Liu Y; Huang C; Zhang L
    Biol Trace Elem Res; 2016 Feb; 169(2):189-203. PubMed ID: 26170171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human serum albumin interaction with oxaliplatin studied by capillary isoelectric focusing with the whole column imaging detection and spectroscopic method.
    Lemma T; Pawliszyn J
    J Pharm Biomed Anal; 2009 Nov; 50(4):570-5. PubMed ID: 19070448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M; Hartinger CG
    Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cys34-PEGylated Human Serum Albumin for Drug Binding and Delivery.
    Mehtala JG; Kulczar C; Lavan M; Knipp G; Wei A
    Bioconjug Chem; 2015 May; 26(5):941-9. PubMed ID: 25918947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A fluorescent reporter detects details of aromatic ligand interference in drug-binding sites of human serum albumin.
    Dobretsov G; Smolina N; Syrejshchikova T; Brilliantova V; Uzbekov M
    Biochem Biophys Res Commun; 2016 Sep; 478(1):462-466. PubMed ID: 27318089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inductively coupled plasma mass spectrometry for metallodrug development: albumin binding and serum distribution of cytotoxic cis- and trans-isomeric platinum(II) complexes.
    Ossipov K; Scaffidi-Domianello YY; Seregina IF; Galanski MS; Keppler BK; Timerbaev AR; Bolshov MA
    J Inorg Biochem; 2014 Aug; 137():40-5. PubMed ID: 24803025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anticancer potency of small linear and cyclic tetrapeptides and pharmacokinetic investigations of peptide binding to human serum albumin.
    Sivertsen A; Tørfoss V; Isaksson J; Ausbacher D; Anderssen T; Brandsdal BO; Havelkova M; Skjørholm AE; Strøm MB
    J Pept Sci; 2014 Apr; 20(4):279-91. PubMed ID: 24677781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.
    Chang SW; Lewis AR; Prosser KE; Thompson JR; Gladkikh M; Bally MB; Warren JJ; Walsby CJ
    Inorg Chem; 2016 May; 55(10):4850-63. PubMed ID: 27143338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Platinum(II)-dendrimer conjugates: synthesis and investigations on cytotoxicity, cellular distribution, platinum release, DNA, and protein binding.
    Kapp T; Dullin A; Gust R
    Bioconjug Chem; 2010 Feb; 21(2):328-37. PubMed ID: 20104885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thermodynamic investigation of interaction between [(η6-p-cymene) RuII(acetone-N4-phenylthiosemicarbazone)Cl]Cl anticancer drug and human serum albumin: spectroscopic and electrochemical studies.
    Huang S; Zhu F; Qian Q; Xiao Q; Su W
    Biol Trace Elem Res; 2015 Mar; 164(1):150-61. PubMed ID: 25475999
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of amantadine hydrochloride binding with IIA subdomain of human serum albumin by fatty acid chains.
    Yang F; Lee P; Ma Z; Ma L; Yang G; Wu X; Liang H
    J Pharm Sci; 2013 Jan; 102(1):84-92. PubMed ID: 23108589
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.
    Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 2000; 45(5):417-22. PubMed ID: 10803926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.
    Groessl M; Tsybin YO; Hartinger CG; Keppler BK; Dyson PJ
    J Biol Inorg Chem; 2010 Jun; 15(5):677-88. PubMed ID: 20213306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human Serum Albumin Nanoparticles as a Novel Delivery System for Cabazitaxel.
    Zhou G; Jin X; Zhu P; Yao JU; Zhang Y; Teng L; Lee RJ; Zhang X; Hong W
    Anticancer Res; 2016 Apr; 36(4):1649-56. PubMed ID: 27069142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.
    Novohradský V; Bergamo A; Cocchietto M; Zajac J; Brabec V; Mestroni G; Sava G
    Dalton Trans; 2015 Jan; 44(4):1905-13. PubMed ID: 25489765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.